Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Emerging therapeutic strategies in breast cancer (Oct 2026)
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles
  • Search Articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Leukemia inhibitory factor inhibits HIV-1 replication and is upregulated in placentae from nontransmitting women
Bruce K. Patterson, Homira Behbahani, William J. Kabat, Yvonne Sullivan, Maurice R.G. O’Gorman, Alan Landay, Zareefa Flener, Nadia Khan, Ram Yogev, Jan Andersson
Bruce K. Patterson, Homira Behbahani, William J. Kabat, Yvonne Sullivan, Maurice R.G. O’Gorman, Alan Landay, Zareefa Flener, Nadia Khan, Ram Yogev, Jan Andersson
View: Text | PDF
Article

Leukemia inhibitory factor inhibits HIV-1 replication and is upregulated in placentae from nontransmitting women

  • Text
  • PDF
Abstract

The placenta may play a critical role in inhibiting vertical transmission of HIV-1. Here we demonstrate that leukemia inhibitory factor (LIF) is a potent endogenous HIV-1–suppressive factor produced locally in placentae. In vitro, LIF exerted a potent, gp130-LIFRβ–dependent, HIV coreceptor–independent inhibition of HIV-1 replication with IC50 values between 0.1 pg/ml and 0.7 pg/ml, depending on the HIV-1 isolate. LIF also inhibited HIV-1 in placenta and thymus tissues grown in ex vivo organ culture. The level of LIF mRNA and the incidence of LIF protein–expressing cells were significantly greater in placentae from HIV-1–infected women who did not transmit HIV-1 to their fetuses compared with women who transmitted the infection, but they were not significantly different from placentae of uninfected mothers. These findings demonstrate a novel pathway for endogenous HIV suppression that may prove to be an effective immune therapy for HIV infection.

Authors

Bruce K. Patterson, Homira Behbahani, William J. Kabat, Yvonne Sullivan, Maurice R.G. O’Gorman, Alan Landay, Zareefa Flener, Nadia Khan, Ram Yogev, Jan Andersson

×

Figure 4

Options: View larger image (or click on image) Download as PowerPoint
Requirement of gp130-LIFRβ for HIV-1 inhibition by LIF is seen. (a) MT-2...
Requirement of gp130-LIFRβ for HIV-1 inhibition by LIF is seen. (a) MT-2 cells do not express gp130-LIFRβ (CD130); however, (b) PBMCs express high levels of gp130-LIFRβ. Dotted lines represent PE-conjugated isotype controls for CD130-LIFRβ staining. (c) MT-2 cells are resistant to and PBMCs susceptible to the HIV-1–inhibitory effects of LIF. Anti-CD130 Ab’s abrogate the anti-HIV-1 effects of LIF. PBMCs and MT-2 cells were infected with 10,000 TCID50 of HIV-1Lai.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts